Regenerative therapy for Diabetes mellitus: MTA1 increases human pancreatic beta cell replication via down regulation of its target gene DYRK1A, 22/April/2015, 8.59 am

Natural product-based therapy for Regenerating the lost cardiomyocytes in Myocardial patients: Hibiscus extract increases the expression of ERBB2 and promotes dedifferentiation of cardiomyocytes via down regulation of its target gene, 22/April/2014, 7.40 am
April 22, 2015
Molecular therapy for Human Cancer: Deltex1 suppresses the expression of Tripeptidyl Peptidase 1 (TPP1) via up regulation of its target gene, 22/April/2015, 9.03 am
April 22, 2015
Show all

A study from the Diabetes, Obesity and Metabolism Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA and Division of Endocrinology and Bone Disease, Icahn School of Medicine at Mount Sinai, New York, New York, USA  shows that “A high-throughput chemical screen reveals that harmine-mediated inhibition of DYRK1A increases human pancreatic beta cell replication.” This study was published in the 9 March  2015 issue of the Journal “Nature Medicine” (the no.1 journal in General Medicine with an impact factor of  28.054) by Prof Stewart AF, Wang P, and others.

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Regenerative therapy for Diabetes mellitus: MTA1 increases human pancreatic beta cell replication via down regulation of its target gene DYRK1A

Significance:   Given that (1)  more than 387 million people worldwide are affected by Diabetes mellitus (DM); (2) the life-long painful injection/drug treatment is required to treat DM; and (3) the global economic cost spent for diabetes treatment in 2014 was little more than 600 billion US dollars, there is an urgent need to find a way to induce regeneration of adult β-cells that were lost in DM. This study suggests, for the first time, that MTA1, by decreasing the expression of its target gene DYRK1A, it may increase/improve: (1) human pancreatic beta cell replication; (2) islet cell mass; and (3) glycemic control. Thus, pharmacological formulations encompassing MTA1 activators may be used to regenerate human adult beta cells.

Idea Proposed/Formulated byDr L Boominathan Ph.D.

Web: http://genomediscovery.org

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

To citeBoominathan, Regenerative therapy for Diabetes mellitus: MTA1 increases human pancreatic beta cell replication via down regulation of its target gene DYRK1A, 22/April/2015, 8.59 am, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Courtesy: When you cite drop us a line at info@genomediscovery.org

* Research cooperation

Undisclosed information: How MTA1 decreases the expression of DYRK1

Comments are closed.